Clinical Trials Directory

Trials / Recruiting

RecruitingNCT02701036

Sporadic Degenerative Ataxia With Adult Onset: Natural History Study

Sporadic Degenerative Ataxia With Adult Onset: Natural History Study (SPORTAX-NHS)

Status
Recruiting
Phase
Study type
Observational
Enrollment
300 (estimated)
Sponsor
Ataxia Study Group · Academic / Other
Sex
All
Age
40 Years
Healthy volunteers
Accepted

Summary

The key goals of SPORTAX-NHS is to compare the phenotype of multiple system atrophy of cerebellar type (MSA-C) and sporadic adult onset ataxia of unknown aetiology (SAOA) and to determine the rate of disease progression in both groups including determination of the factors that predict the development of MSA-C vs. SAOA, and at which time after onset of ataxia, a reliable distinction between both disorders is possible. The planned study will also allow to collect blood samples and other biomaterials from patients with sporadic ataxia, which will be useful for future genetic and biomarker studies.

Detailed description

Progressive ataxia frequently starts in adults without a familial background. These patients may suffer from an acquired ataxia or a genetically determined ataxia despite negative family history. In the majority of them, however, a genetic or acquired cause of ataxia cannot be identified suggesting a sporadic degenerative ataxia. They can be subdivided into two groups. In one group, the underlying brain disease is multiple system atrophy (MSA), specifically MSA of cerebellar type (MSA-C). The characteristic clinical feature of MSA is the presence of severe autonomic failure defined by orthostatic hypotension or urinary incontinence. The second group is distinguished from MSA-C by the lasting absence of severe autonomic failure. These patients have been designated as sporadic adult onset ataxia of unknown aetiology (SAOA). In the first years after ataxia onset, a distinction between MSA-C and SAOA is often not possible. There are only few studies comparing the phenotype of MSA-C and SAOA, and longitudinal studies focussing on the evolution of the phenotype of these disorders are completely lacking. In particular, the progression rate of SAOA compared to MSA-C has not been defined. In addition, it is unknown which factors predict the development of MSA-C vs. SAOA, and at which time after onset of ataxia, a reliable distinction between both disorders is possible. To answer these questions, we plan to create a European registry of patients with sporadic degenerative ataxia of adult onset and to perform a natural history study. The planned study will also allow to collect blood samples and other biomaterials from patients with sporadic ataxia, which will be useful for future genetic and biomarker studies.

Conditions

Timeline

Start date
2010-04-01
Primary completion
2030-12-01
Completion
2030-12-01
First posted
2016-03-08
Last updated
2017-06-29

Locations

14 sites across 5 countries: Austria, Germany, Italy, Netherlands, Norway

Source: ClinicalTrials.gov record NCT02701036. Inclusion in this directory is not an endorsement.